

Investor Relations

Chris Tyson
Executive Vice President
MZ North America
+1-949-491-8235
BEAT@mzgroup.us

NASDAQ: BEAT

Share Price ¹	\$0.68
Proforma Market Cap ²	\$37.7M
Proforma Cash & Cash Equivalents ²	\$12.4M
Proforma Shares Out ²	55.5M
Float ³	33.9M

1) As of July 9, 2026

2) Proforma — Q1 2026 10-Q + April/May 2026 Offering & Overallotment


3) Source: Yahoo Finance

How to Use the HeartBeam System



HeartBeam is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions (our TriCor technology), and synthesizing the signals into a 12-lead ECG for arrhythmia assessment. In the future, the company's TriCor 3D signal technology platform can be used with various portable form factors that are with the patient at all times to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.

One platform. Many form factors.
The most info rich ambulatory ECG signal.



**FDA Cleared for arrhythmia assessment only. Heart attack detection and AI are future indications*

Executing on a \$40B Cardiac Monitoring Platform Opportunity

- **Ability to serve 50M+ patients** across multiple applications and form factors
- Rapidly advancing clinical validation to support **indication expansion into Heart Attack Detection**
- Patch and ruggedized device form factors provide **opportunity to access rural US and developing world markets** to further expand TAMs
- **On-Demand 12-Lead Patch** poised to disrupt \$2B patch market
- **Strong IP: 25+ Issued Patents Worldwide**
- **FDA 510(k) Clearances for Arrhythmia Detection:**
 - 12/2024: The HeartBeam System
 - 12/2025: 12-Lead Synthesis Algorithm

Cleared Indications for Use

The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Heart Attack Detection, AI algorithm and 12-lead patch products are not cleared by FDA and not available for sale in the United States or other geographies. Refer to the Company's Cleared Indications for Use at [HeartBeam Indications](#) for details on the intended use of its technology.



Growing Body of Clinical Evidence



- Demonstrated similar accuracy to a standard 12L ECG for common arrhythmias
- 94% sensitivity and 100% specificity in detecting common arrhythmias compared to standard 12L ECG in VALID-ECG pivotal study
- Completed proof-of-concept studies supporting future use for heart attack detection and AI algorithms.



On-Demand 12-Lead Patch¹: Disrupting the Patch Market

TODAY'S PATCH MARKET

\$2B revenue market with existing reimbursement

Devices are 1-3 leads, which limit applications to arrhythmia detection and monitoring

Mobile Cardiac Telemetry (MCT) segment has highest reimbursement and fastest growth

Sources: ReAnIn Reports, GM Insights



[Watch the video](#)



Clinical grade 12-Lead ECG in a patch form factor

Continuous 1-Lead mode matches performance of existing systems

On-demand 12-Lead ECG mode **expands segment into ischemia detection**

Pilot study to detect ischemia initiated

Positioned to take share and expand patch market

Heart Attack Detection¹

Clinical validation to support indication expansion into heart attack detection is rapidly advancing. ALIGN-ACS pilot study completed enrollment ahead of schedule; data analysis underway.

20M+ high-risk patients in the U.S.

Patients can't recognize a heart attack at home
12-Lead ECG is only in hospitals
3-4 hour delays = death or heart failure

Why We Win

Clinical data shows HeartBeam is similar to standard 12-Lead ECG

Baseline ECG improves accuracy over single ECG

Same device → expanded indication


No other solution can offer this outside traditional care settings

Accelerating Partnerships and AI-ECG Algorithms¹

- An AI-ready signal, built for more than cardiac care
- Focused on licensing 3D ECG signal technology to established partners, **moving beyond direct medical device sales**



- **Accelerates development of personalized cardiac AI algorithms** across use cases including **assessing heart attack risk**.
- **Expands HeartBeam** beyond rhythm monitoring **into longitudinal 12-lead ECG monitoring** anytime, anywhere



De Luca G. Circulation. 2004 Mar 16;109(10):1223-5 Heidenreich PA, J Card Fail. 2022 Mar;28(3):453-466.

¹FDA cleared for arrhythmia assessment only. Heart attack detection, AI algorithm, and 12-Lead patch products not cleared by FDA and not available for sale in the United States or other geographies.

DISCLAIMER: This information is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy any security or related financial instrument or to participate in any trading strategy. The summary may include "forward-looking statements" with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934 and are intended to be covered by the safe harbor provisions for forward looking statements. This information is supplied from sources we believe to be reliable, but we cannot guarantee accuracy. This document has been furnished to you solely for your information.